216 related articles for article (PubMed ID: 25249301)
1. Silencing the expression of Cbl-b enhances the immune activation of T lymphocytes against RM-1 prostate cancer cells in vitro.
Zhou SK; Chen WH; Shi ZD; Wang SP; Li L; Wen XF; Wang YM
J Chin Med Assoc; 2014 Dec; 77(12):630-6. PubMed ID: 25249301
[TBL] [Abstract][Full Text] [Related]
2. Cbl-b gene silencing in splenic T lymphocytes as a therapeutic strategy to target the prostate cancer RM-1 cell tumors in immune competent mice.
Shi ZD; Li XF; Hao L; Zhao Y; Wang YX; Dong BZ; Chen WH; Zhang ZG; Wang YM; Fu Q; Han CH; Li S
Eur Rev Med Pharmacol Sci; 2014; 18(24):3819-30. PubMed ID: 25555872
[TBL] [Abstract][Full Text] [Related]
3. [
Chen S; Li Z; Zhou L; Zhang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2019 May; 39(5):554-560. PubMed ID: 31140419
[TBL] [Abstract][Full Text] [Related]
4. Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions.
Paolino M; Thien CB; Gruber T; Hinterleitner R; Baier G; Langdon WY; Penninger JM
J Immunol; 2011 Feb; 186(4):2138-47. PubMed ID: 21248250
[TBL] [Abstract][Full Text] [Related]
5. Cutting edge: deficiency in the E3 ubiquitin ligase Cbl-b results in a multifunctional defect in T cell TGF-beta sensitivity in vitro and in vivo.
Wohlfert EA; Gorelik L; Mittler R; Flavell RA; Clark RB
J Immunol; 2006 Feb; 176(3):1316-20. PubMed ID: 16424156
[TBL] [Abstract][Full Text] [Related]
6. Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice.
Stromnes IM; Blattman JN; Tan X; Jeevanjee S; Gu H; Greenberg PD
J Clin Invest; 2010 Oct; 120(10):3722-34. PubMed ID: 20890046
[TBL] [Abstract][Full Text] [Related]
7. The role of the e3 ligase cbl-B in murine dendritic cells.
Wallner S; Lutz-Nicoladoni C; Tripp CH; Gastl G; Baier G; Penninger JM; Stoitzner P; Wolf D
PLoS One; 2013; 8(6):e65178. PubMed ID: 23762309
[TBL] [Abstract][Full Text] [Related]
8. Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth.
Kawakita M; Rao GS; Ritchey JK; Ornstein DK; Hudson MA; Tartaglia J; Paoletti E; Humphrey PA; Harmon TJ; Ratliff TL
J Natl Cancer Inst; 1997 Mar; 89(6):428-36. PubMed ID: 9091644
[TBL] [Abstract][Full Text] [Related]
9. Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine.
Lutz-Nicoladoni C; Wallner S; Stoitzner P; Pircher M; Gruber T; Wolf AM; Gastl G; Penninger JM; Baier G; Wolf D
Immunol Cell Biol; 2012 Jan; 90(1):130-4. PubMed ID: 21383769
[TBL] [Abstract][Full Text] [Related]
10. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b.
Bachmaier K; Krawczyk C; Kozieradzki I; Kong YY; Sasaki T; Oliveira-dos-Santos A; Mariathasan S; Bouchard D; Wakeham A; Itie A; Le J; Ohashi PS; Sarosi I; Nishina H; Lipkowitz S; Penninger JM
Nature; 2000 Jan; 403(6766):211-6. PubMed ID: 10646608
[TBL] [Abstract][Full Text] [Related]
11. Visualizing the role of Cbl-b in control of islet-reactive CD4 T cells and susceptibility to type 1 diabetes.
Hoyne GF; Flening E; Yabas M; Teh C; Altin JA; Randall K; Thien CB; Langdon WY; Goodnow CC
J Immunol; 2011 Feb; 186(4):2024-32. PubMed ID: 21248249
[TBL] [Abstract][Full Text] [Related]
12. [Down-regulation of TIPE2 promotes the proliferation and immune activity of T lymphocytes].
Huang L; Chen J; Hong B
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Jul; 32(7):886-90. PubMed ID: 27363266
[TBL] [Abstract][Full Text] [Related]
13. The role of tumor cells in the modification of T lymphocytes activity--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ cells in squamous cell laryngeal carcinoma. Part I.
Starska K; Głowacka E; Kulig A; Lewy-Trenda I; Bryś M; Lewkowicz P
Folia Histochem Cytobiol; 2011; 49(4):579-92. PubMed ID: 22252752
[TBL] [Abstract][Full Text] [Related]
14. A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells.
Lund ME; Howard CB; Thurecht KJ; Campbell DH; Mahler SM; Walsh BJ
BMC Cancer; 2020 Dec; 20(1):1214. PubMed ID: 33302918
[TBL] [Abstract][Full Text] [Related]
15. Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model.
Hinterleitner R; Gruber T; Pfeifhofer-Obermair C; Lutz-Nicoladoni C; Tzankov A; Schuster M; Penninger JM; Loibner H; Lametschwandtner G; Wolf D; Baier G
PLoS One; 2012; 7(9):e44295. PubMed ID: 22962608
[TBL] [Abstract][Full Text] [Related]
16. Differential control of CD28-regulated in vivo immunity by the E3 ligase Cbl-b.
Krawczyk CM; Jones RG; Atfield A; Bachmaier K; Arya S; Odermatt B; Ohashi PS; Penninger JM
J Immunol; 2005 Feb; 174(3):1472-8. PubMed ID: 15661906
[TBL] [Abstract][Full Text] [Related]
17. Deletion of Cbl-b inhibits CD8
Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
[TBL] [Abstract][Full Text] [Related]
18. Ubiquitin Ligases CBL and CBL-B Maintain the Homeostasis and Immune Quiescence of Dendritic Cells.
Tong H; Li X; Zhang J; Gong L; Sun W; Calderon V; Zhang X; Li Y; Gadzinski A; Langdon WY; Reizis B; Zou Y; Gu H
Front Immunol; 2021; 12():757231. PubMed ID: 34630435
[TBL] [Abstract][Full Text] [Related]
19. Negative regulation of CD40-mediated B cell responses by E3 ubiquitin ligase Casitas-B-lineage lymphoma protein-B.
Qiao G; Lei M; Li Z; Sun Y; Minto A; Fu YX; Ying H; Quigg RJ; Zhang J
J Immunol; 2007 Oct; 179(7):4473-9. PubMed ID: 17878343
[TBL] [Abstract][Full Text] [Related]
20. Cbl-b(-/-) T cells demonstrate in vivo resistance to regulatory T cells but a context-dependent resistance to TGF-beta.
Adams CO; Housley WJ; Bhowmick S; Cone RE; Rajan TV; Forouhar F; Clark RB
J Immunol; 2010 Aug; 185(4):2051-8. PubMed ID: 20624942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
